CareDx, Inc (NASDAQ:CDNA - Get Free Report)'s stock price fell 4.6% on Thursday . The company traded as low as $19.14 and last traded at $19.15. 402,514 shares were traded during trading, a decline of 56% from the average session volume of 911,156 shares. The stock had previously closed at $20.08.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on CDNA shares. The Goldman Sachs Group decreased their price objective on shares of CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. HC Wainwright reaffirmed a "neutral" rating and issued a $25.00 price objective on shares of CareDx in a research note on Monday, May 5th. Wall Street Zen lowered shares of CareDx from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Finally, Stephens reissued an "overweight" rating and set a $40.00 target price on shares of CareDx in a research note on Monday, May 5th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $30.33.
View Our Latest Report on CDNA
CareDx Price Performance
The firm has a market capitalization of $1.04 billion, a P/E ratio of -6.89 and a beta of 2.18. The stock's 50 day moving average is $17.50 and its two-hundred day moving average is $20.24.
CareDx (NASDAQ:CDNA - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.06 by $0.03. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The firm had revenue of $84.69 million during the quarter, compared to the consensus estimate of $84.56 million. During the same quarter in the prior year, the firm earned ($0.03) earnings per share. The business's quarterly revenue was up 17.6% on a year-over-year basis. As a group, equities research analysts expect that CareDx, Inc will post -0.9 EPS for the current year.
Insider Buying and Selling
In related news, Director Peter Maag sold 13,281 shares of the firm's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $17.23, for a total transaction of $228,831.63. Following the transaction, the director now directly owns 316,743 shares of the company's stock, valued at approximately $5,457,481.89. This trade represents a 4.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christine Cournoyer sold 16,700 shares of the firm's stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $14.13, for a total transaction of $235,971.00. Following the transaction, the director now directly owns 37,045 shares in the company, valued at approximately $523,445.85. This represents a 31.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 108,773 shares of company stock worth $1,843,890. 4.40% of the stock is owned by insiders.
Institutional Investors Weigh In On CareDx
Hedge funds have recently made changes to their positions in the stock. Sterling Capital Management LLC boosted its stake in shares of CareDx by 771.2% in the 4th quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock valued at $27,000 after purchasing an additional 1,126 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in CareDx by 20,200.0% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,466 shares of the company's stock worth $79,000 after buying an additional 4,444 shares during the period. Tower Research Capital LLC TRC boosted its position in CareDx by 553.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company's stock worth $84,000 after buying an additional 3,322 shares during the period. State of Wyoming acquired a new stake in CareDx during the 4th quarter worth approximately $91,000. Finally, Morse Asset Management Inc acquired a new stake in CareDx during the 1st quarter worth approximately $103,000.
CareDx Company Profile
(
Get Free Report)
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
See Also
Before you consider CareDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.
While CareDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
